Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor, Adult × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 134 Neoplasm Metastasis 18 Neoplasms 17 Advanced Breast Cancer 11 Ovarian Neoplasms 9 Endometrial Neoplasms 8 Hereditary Sensory and Autonomic Neuropathies 7 Carcinoma, Non-Small-Cell Lung 7 Triple Negative Breast Neoplasms 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Neoplasms by Site 4 Multiple Endocrine Neoplasia Type 1 4 Colorectal Neoplasms 4 Breast Diseases 4 Recurrence 3 Head and Neck Neoplasms 3 Stomach Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Liposarcoma 2 Carcinoma, Ovarian Epithelial 2 Advanced Solid Tumors 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumor, Adult 1 Solid Malignancies 1 Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 5 Proton Therapy 3 spartalizumab 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Cetuximab 2 toripalimab 1 sotorasib 1 peposertib 1 necitumumab 1 leronlimab 1 abemaciclib 1 Valganciclovir 1 Trastuzumab 1 Therapeutics 1 Radiotherapy 1 PankoMab-GEX 1 Panitumumab 1 MEK inhibitor I 1 Jupiter 1 Ipilimumab 1 Interleukin-2 1 GAT 1 Fulvestrant 1 FCN-437c 1 EBI-005 1 Docetaxel 1 Catalytic Domain 1 Carboplatin 1 CS-1003 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04092673 2024-05-21

Zotatifin

Effector Therapeutics

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡